Gilead Sciences, Inc. (NASDAQ: GILD) and Pharmstandard today announced that they have entered into an agreement that grants Pharmstandard rights to manufacture Sovaldi® (sofosbuvir) for the treatment of chronic hepatitis C and Truvada® (emtricitabine/tenofovir disoproxil fumarate) for the treatment of HIV.
“Hepatitis C and HIV are significant public health issues worldwide, including in Russia. We believe that this partnership will help facilitate access to Gilead’s innovative therapies for many people in Russia and enabling them to live longer and healthier lives,” said Igor Rukavishnikov, General Manager of Gilead Russia.
"We are proud of our partnership with Gilead, the world leader in the production of innovative drugs for the treatment of HIV infection and chronic viral hepatitis. For both companies, this is a very important step, which confirms the seriousness of our intentions in increasing of drug therapy availability for Russian patients. The first shipment of drugs will be delivered to the market in 2019. In general, we are focused on the long-term perspective and expansion of our cooperation in the transition to a completely new innovative level of medical care for patients with chronic infectious diseases. This will significantly reduce the epidemiological increase in morbidity, improve the quality and life time of patients. We are confident that as a result of the implementation of our project, we will be able fully meet the need for antiretroviral and antiviral drugs in Russia." - Grigoriy Potapov, General Director of JSC Pharmstandard.
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Today, it’s estimated that more than 10 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.
Gilead has helped revolutionize the treatment of chronic hepatitis C infection by providing medicines that offer cure rates as high as 95, 99 percent for all genotypes (1-6) of HCV infection in less time and with fewer side effects than prior treatments.
Pharmstandard is a leading Russian pharmaceutical company which develops and manufactures high-quality, affordable and innovative pharmaceutical products to satisfy the needs of patients and the Russian healthcare system. Pharmstandard manufactures more than 330 medicines, more than 140 out of which are included in the List of Vital and Essential Drugs. The pharmaceutical portfolio of the company includes pharmaceutical products for the treatment of cardiovascular diseases, diabetes mellitus, growth hormone deficiency, gastroenterological and infectious diseases, neurological disorders, metabolic disorders, oncology, and a variety of other diseases.
The manufacturing capabilities of Pharmstandard are represented by five manufacturing plants and located across the Russian Federation. Pharmstandard’s state-of-the-art manufacturing facilities correspond to GMP standards and are certified by Russian and EU regulatory bodies. Under partnership agreements with international pharmaceutical companies, Pharmstandard has localized and manufactured high quality innovative pharmaceutical products.
Pharmstandard is a leading Russian company and one of the biggest distributors of pharmaceutical products in Russia. The company supplies its products throughout Russia and abroad.